Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Cleveland BioLabs has signed a $4 million agreement with the Russian Ministry of Industry & Trade for CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. The contract, issued under Russia’s Pharma 2020 initiative, provides funding over a three-year period to support research through Phase II clinical trials. Cleveland BioLabs says CBLB612 is a candidate for use in bone marrow transplants.
This article has been sent to the following recipient: